Search

Your search keyword '"Dissegna D."' showing total 4 results
Start Over Author "Dissegna D." Topic 03 medical and health sciences
4 results on '"Dissegna D."'

1. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D

Author

Lampertico, Pietro, Brunetto, Maurizia R., Craxì, Antonio, Gaeta, Giovanni B., Rizzetto, Mario, Rozzi, Antonella, Colombo, Massimo, Antonio, D., Andreone, P., Brancaccio, G., Bronte, F., Bruzzone, L., Caccamo, G., Caccianotti, B., Calvaruso, V., Chessa, L., Ciarallo, M., Coco, B., Colombatto, P., Cursaro, C., D'Aluisio, D., Demelia, L., Di Marco, V., Dissegna, D., Invernizzi, F., Lenisa, I., Lembo, T., Levrero, M., Marchese, V., Mangia, G., Picciotto, A., Pierconti, S., Raimondo, G., Rastelli, C., Rizzo, V., Santantonio, T., Scuteri, A., Sorbello, O., Squadrito, G., Subic, M., Toniutto, P., Vukotic, R., Lampertico, Pietro, Brunetto, Maurizia R., Craxì, Antonio, Gaeta, Giovanni B., Rizzetto, Mario, Rozzi, Antonella, Colombo, Massimo, Antonio, D., Andreone, P., Brancaccio, G., Bronte, F., Bruzzone, L., Caccamo, G., Caccianotti, B., Calvaruso, V., Chessa, L., Ciarallo, M., Coco, B., Colombatto, P., Cursaro, C., D'Aluisio, D., Demelia, L., Di Marco, V., Dissegna, D., Invernizzi, F., Lenisa, I., Lembo, T., Levrero, M., Marchese, V., Mangia, G., Picciotto, A., Pierconti, S., Raimondo, G., Rastelli, C., Rizzo, V., Santantonio, T., Scuteri, A., Sorbello, O., Squadrito, G., Subic, M., Toniutto, P., Vukotic, R., Brunetto, Maurizia R, Gaeta, Giovanni B, Brancaccio, Giuseppina, Lampertico P1, Brunetto MR2, Craxì Antonio, Gaeta GB4, Rizzetto M5, Rozzi A6, Colombo M7, and Antonio D, Andreone P, Antonio D, Brancaccio G, Bronte F, Bruzzone L, Caccamo G, Caccianotti B, Calvaruso V, Chessa L, Ciarallo M, Coco B, Colombatto P, Cursaro C, D'Aluisio D, Demelia L, Di Marco V, Dissegna D, Invernizzi F, Lenisa I, Lembo T, Levrero M, Marchese V, Mangia G, Picciotto A, Pierconti S, Antonio D, Raimondo G, Rastelli C, Rizzo V, Santantonio T, Scuteri A, Sorbello O, Squadrito G, Subic M, Toniutto P, Vukotic R.

Subjects
Male, HBsAg, Gastroenterology, Polyethylene Glycols, chronic hepatitis B, HBeAg-negative, nucleos(t)ide analogues, peginterferon, treatment, Hepatology, Infectious Diseases, Virology, 0302 clinical medicine, Interferon, Genotype, HBV, Hepatitis B e Antigens, chronic hepatitis b, hbeag-negative, adult, antiviral agents, drug administration schedule, drug therapy, combination, female, genotype, hepatitis b e antigens, hepatitis b virus, hepatitis b, chronic, humans, interferon-alpha, male, middle aged, nucleosides, polyethylene glycols, recombinant proteins, treatment outcome, education.field_of_study, virus diseases, Nucleosides, Middle Aged, Recombinant Proteins, Treatment Outcome, nucleos(t)ide analogue, HBeAg, 030220 oncology & carcinogenesis, Drug Therapy, Combination, Female, 030211 gastroenterology & hepatology, Peginterferon alfa-2a, medicine.drug, Adult, Hepatitis B virus, medicine.medical_specialty, Combination therapy, Population, Infectious Disease, Antiviral Agents, Drug Administration Schedule, 03 medical and health sciences, Hepatitis B, Chronic, Internal medicine, medicine, Humans, education, business.industry, Interferon-alpha, Confidence interval, business
Abstract

Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA

Published
2019

2. Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV

Author

Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, Villa, Erica, Craxì, A., Petta, S., Calvaruso, V., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Federico, A., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Karampatou, A., Han, X., Kondili, L., Taliani, G., Ciancio, A., Morisco, F., Critelli, R., Baraldi, E., Bernabucci, V., Troshina, G., Guarino, M., Tagliavini, S., D'Ambrosio, F., Bristot, L., Turco, L., Rosato, S., Vella, S., Trenti, T., Neri, I., La Marca, A., Manthena, S., Goldstein, A., Bruno, S., Bao, Y., Gonzalez, Y., Villa, E., Craxi, A., Petta, S., Calvaruso, V., Karampatou, A, Han, X, Kondili, L, Taliani, G, Ciancio, A, Morisco, F, Critelli, R, Baraldi, E, Bernabucci, V, Troshina, G, Guarino, M, Tagliavini, S, D'Ambrosio, F, Bristot, L, Turco, L, Rosato, S, Vella, S, Trenti, T, Neri, I, La Marca, A, Manthena, S, Goldstein, A, Bruno, S, Bao, Y, Gonzalez, Y, Villa, E, Craxi, A, Petta, S, Calvaruso, V, Brunetto, M, Coco, B, Chessa, L, Pasetto, M, Bigliotti, E, Tamburrini, F, Montalto, G, Capitano, A, Ieluzzi, D, Fattovich, G, Zignego, A, Monti, M, Gragnani, L, Zuin, M, Finati, E, Giorgini, A, Angarano, G, Milella, M, Alessandro, F, Dallio, M, Mazzella, G, Lazzarini, G, Di Fine, M, Russo, F, Zanetto, A, Castelli, F, Zaltron, S, Raimondo, G, Filomia, R, Puoti, M, Danieli, E, Strazzabosco, M, Gemma, M, Angelico, M, De Leonardis, F, Gori, A, Cappelletti, E, Bruno, R, Cima, S, Coppola, C, Amoruso, D, Andreone, P, Simonetti, G, Gaeta, G, Brancaccio, G, Toniutto, P, Dissegna, D, Mondelli, M, Ludovisi, S, Persico, M, Masarone, M, Torti, C, Strazzulla, A, Rosina, F, Framarin, L, Weimer, L, Quaranta, M, Falzano, L, Mallano, A, Karampatou, Aimilia, Han, Xue, Kondili, Loreta A., Taliani, Gloria, Ciancio, Alessia, Morisco, Filomena, Critelli, Rosina Maria, Baraldi, Enrica, Bernabucci, Veronica, Troshina, Giulia, Guarino, Maria, Tagliavini, Simonetta, D'Ambrosio, Federica, Bristot, Laura, Turco, Laura, Rosato, Stefano, Vella, Stefano, Trenti, Tommaso, Neri, Isabella, La Marca, Antonio, Manthena, Shivaji, Goldstein, Andrea S., Bruno, Savino, Bao, Yanjun, Gonzalez, Yuri Sanchez, Villa, Erica, Craxì, A., Brunetto, M., Coco, B., Chessa, L., Pasetto, M. C., Bigliotti, E., Tamburrini, F., Montalto, G., Capitano, A. R., Ieluzzi, D., Fattovich, G., Zignego, A. L., Monti, M., Gragnani, L., Zuin, M., Finati, E., Giorgini, A., Angarano, G., Milella, M., Alessandro, F., Dallio, M., Mazzella, G., Lazzarini, G., Di Fine, M., Russo, F. P., Zanetto, A., Castelli, F., Zaltron, S., Raimondo, G., Filomia, R., Puoti, M., Danieli, E., Strazzabosco, M., Gemma, M., Angelico, M., De Leonardis, F., Gori, A., Cappelletti, E., Bruno, R., Cima, S., Coppola, C., Amoruso, D. C., Andreone, P., Simonetti, G., Gaeta, G. B., Brancaccio, G., Toniutto, P., Dissegna, D., Mondelli, M., Ludovisi, S., Persico, M., Masarone, M., Torti, C., Strazzulla, A., Rosina, F., Framarin, L., Weimer, L. E., Quaranta, M. G., Falzano, L., Mallano, A., Pasetto, M.C., Capitano, A.R., Zignego, A.L., Russo, F.P., Amoruso, D.C., Gaeta, G.B., Weimer, L.E., Quaranta, M.G., Craxã¬, A., and Federico, A.

Subjects
Anti-Mullerian hormone, Antiviral therapy, HBV, HCV, Sustained viral response, Hepatology, Infertility, medicine.medical_specialty, media_common.quotation_subject, Fertility, Anti-Müllerian hormone, Miscarriage, 03 medical and health sciences, 0302 clinical medicine, Medicine, Prospective cohort study, media_common, Gynecology, Anti-Müllerian hormone, Antiviral therapy, HBV, HCV, Sustained viral response, 030219 obstetrics & reproductive medicine, business.industry, Obstetrics, medicine.disease, Anti-Müllerian hormone, Gestational diabetes, Cohort, 030211 gastroenterology & hepatology, business, Live birth, Cell aging
Abstract

Background & Aims Premenopausal women who are HCV positive (HCV+) have failing ovarian function, which is likely to impact their fertility. Thus, we investigated the reproductive history, risk of infertility, and pregnancy outcomes in women of childbearing age who were HCV+. Methods Three different groups were studied: (1) Clinical cohort: 100 women who were HCV+ and also had chronic liver disease (CLD), age matched with 50 women who were HBV+ with CLD and with 100 healthy women; all women were consecutively observed in three gastroenterology units in hospitals in Italy; (2) 1,998 women who were HCV+ and enrolled in the Italian Platform for the Study of Viral Hepatitis Therapies (PITER); (3) 6,085 women, who were mono-infected with HCV, and 20,415 women, who were HCV−, from a large de-identified insurance database from the USA. Measurements: total fertility rate (TFR) defined as the average number of children that a woman would bear during her lifetime. To define the reproductive stage of each participant, levels of anti-Müllerian hormone (AMH) and 17β-estradiol were measured. Results Clinical cohort: women who were either HCV+ or HBV+ had similar CLD severity and age at first pregnancy. Based on a multivariate analysis, women who were HCV+ had a higher risk of miscarriage than those who were HBV+ (odds ratio [OR] 6,905; 95% CI 1.771–26.926). Among women who were HCV+, incidence of miscarriage was correlated with median AMH level (1.0 ng/ml). Achieving a sustained virologic response (SVR) after antiviral treatment reduced the risk of miscarriage (OR 0.255; 95% CI 0.090–0.723). In the PITER-HCV cohort, miscarriage occurred in 42.0% of women (44.6% had multiple miscarriages). TFR for women who were HCV+ and between 15 and 49 years of age was 0.7 vs. 1.37 of Italian population of the same age range. In the US cohort: compared with women who were HCV−, women who were HCV+ positive were significantly more likely to have infertility (OR 2.439; 95% CI 2.130–2.794), premature birth (OR 1.34; 95% CI 1.060–1.690), gestational diabetes (OR 1.24; 95% CI 1.020–1.510), and pre-eclampsia (OR 1.206; 95% CI 0.935–1.556), and were less likely to have a live birth (OR 0.754; 95% CI 0.622–0.913). Conclusions Ovarian senescence in women of childbearing age who are HCV+ is associated with a lower chance of live birth, greater risk of infertility, gestational diabetes, pre-eclampsia and miscarriage. Such risks could be positively influenced by successful HCV cure. Lay summary Most new cases of HCV infection are among people who inject drugs, many of whom are young women in their childbearing years. Women of reproductive age who are HCV+ display markers of ovarian senescence. This is associated with an increased burden in terms of infertility and adverse pregnancy outcomes, including stillbirth, miscarriage, fewer live births, and gestational diabetes. Early viral suppression with therapy is likely to mitigate these risks.

Published
2017

3. Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition

Author

Zoccali, Carmine, Ruggenenti, Piero, Perna, Annalisa, Leonardis, Daniela, Tripepi, Rocco, Tripepi, Giovanni, Mallamaci, Francesca, Remuzzi, Giuseppe, 'REIN Study Group' including Remuzzi, G, Tognoni, G, Ruggenenti, P, Bossini, N, Viola, Bf, Scolari, F, Maiorca, R, Cofano, F, Fellin, G, D'Amico, G, Dissegna, D, Brendolan, A, La Greca, G, Feriozzi, A, Ancarani, E, Gandini, E, D'Amato, I, Giangrande, A, Giannico, G, Vitale, O, Manno, C, Schena, Fp, Mazzi, A, Garini, G, Borghetti, A, Pisoni, R, Mosconi, L, Bertani, T, Scanferla, F, Bazzato, G, Oliva, E, Zoccali, C, Toti, G, Sisca, S, Maggiore, Q, Pignone, E, Boero, R, Piccoli, Giorgina Barbara, Piperno, R, Rosati, A, Salvadori, M, Ene Iordache, B, Remuzzi, A, Perna, A, Benini, R, Tammuzzo, L, Gaspari, F, Arnoldi, F, Ciocca, I, Signorini, O, Ferrari, S, Gritti, D, Roggeri, A, Del Priore, L, Cattaneo, D, Stucchi, N, Migone, L, Marubini, E, Del Favero, A, Ideo, G, Geraci, E, and Loi, U.

Subjects
Ramipril, Adult, Male, medicine.medical_specialty, 030232 urology & nephrology, Urology, Angiotensin-Converting Enzyme Inhibitors, 030204 cardiovascular system & hematology, Aged, Disease Progression, Female, Humans, Middle Aged, Phosphates, Randomized Controlled Trials as Topic, Renal Insufficiency, Chronic, Renin-Angiotensin System, Nephrology, Nephropathy, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Internal medicine, Renin–angiotensin system, medicine, Renal Insufficiency, Chronic, Risk factor, Ace inhibition, Creatinine, business.industry, Confounding, General Medicine, Phosphate, medicine.disease, 3. Good health, Endocrinology, chemistry, business, medicine.drug
Abstract

Phosphate may promote the onset and progression of chronic nephropathies. Here we evaluated the relationships between baseline serum phosphate levels, disease progression, and response to ACE inhibition in 331 patients with proteinuric nephropathies in the prospective Ramipril Efficacy In Nephropathy (REIN) trial. Independent of treatment, patients with phosphate levels in the highest two quartiles progressed significantly faster either to ESRD or to a composite endpoint of doubling of serum creatinine or ESRD compared with patients with phosphate levels below the median (P < 0.001). Results were similar when we analyzed phosphate as a continuous variable (P ≤ 0.004). The renoprotective effect of ramipril decreased as serum phosphate increased (P ≤ 0.008 for interaction); this modification of the treatment effect by phosphate persisted despite adjusting for potential confounders such as GFR and urinary protein. In summary, these data suggest that phosphate is an independent risk factor for progression of renal disease among patients with proteinuric CKD, and high levels of phosphate may even attenuate the renoprotective effect of ACE inhibitors. Future trials should test whether reducing serum phosphate improves renal outcomes and optimizes the renoprotective effect of ACE inhibition.

Published
2011

4. Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study

Author

Kondili, Loreta A., GAETA, Giovanni Battista, Ieluzzi, Donatella, Zignego, Anna Linda, Monti, Monica, Gori, Andrea, Soria, Alessandro, Raimondo, Giovanni, Filomia, Roberto, Leo, Alfredo Di, Iannone, Andrea, Massari, Marco, Corsini, Romina, Gulminetti, Roberto, Comini, Alberto Gatti, Toniutto, Pierluigi, Dissegna, Denis, Russo, Francesco Paolo, Zanetto, Alberto, Rumi, Maria Grazia, Brancaccio, Giuseppina, Danieli, Elena, Brunetto, Maurizia Rossana, Weimer, Liliana Elena, Quaranta, Maria Giovanna, Vella, Stefano, Puoti, Massimo, PITER Cohort Study, FEDERICO, Alessandro, Dallio, M, LOGUERCIO, Carmelina, Kondili, L, Gaeta, G, Ieluzzi, D, Zignego, A, Monti, M, Gori, A, Soria, A, Raimondo, G, Filomia, R, Leo, A, Iannone, A, Massari, M, Corsini, R, Gulminetti, R, Comini, A, Toniutto, P, Dissegna, D, Russo, F, Zanetto, A, Rumi, M, Brancaccio, G, Danieli, E, Brunetto, M, Weimer, L, Quaranta, M, Vella, S, Puoti, M, Kondili, Loreta A., Gaeta, Giovanni Battista, Ieluzzi, Donatella, Zignego, Anna Linda, Monti, Monica, Gori, Andrea, Soria, Alessandro, Raimondo, Giovanni, Filomia, Roberto, Leo, Alfredo Di, Iannone, Andrea, Massari, Marco, Corsini, Romina, Gulminetti, Roberto, Comini, Alberto Gatti, Toniutto, Pierluigi, Dissegna, Deni, Russo, Francesco Paolo, Zanetto, Alberto, Rumi, Maria Grazia, Brancaccio, Giuseppina, Danieli, Elena, Brunetto, Maurizia Rossana, Weimer, Liliana Elena, Quaranta, Maria Giovanna, Vella, Stefano, Puoti, Massimo, PITER Cohort, Study, Federico, Alessandro, Dallio, M, and Loguercio, Carmelina

Subjects
Genetics and Molecular Biology (all), Male, Cirrhosis, Disease, Hepacivirus, Toxicology, Biochemistry, Viral infection, 0302 clinical medicine, 80 and over, Medicine, Prospective Studies, Chronic, lcsh:Science, media_common, Aged, 80 and over, Liver Diseases, Drug Interaction, Italy, Adult, Aged, Antiviral Agents, Drug Administration Schedule, Drug Therapy, Combination, Female, Hepatitis C, Chronic, Humans, Interferons, Liver Cirrhosis, Middle Aged, Risk, Drug Interactions, Medicine (all), Biochemistry, Genetics and Molecular Biology (all), Agricultural and Biological Sciences (all), 030220 oncology & carcinogenesis, Interferon, 030211 gastroenterology & hepatology, Human, Cohort study, Drug, medicine.medical_specialty, media_common.quotation_subject, Drug-Drug Interactions, Gastroenterology and Hepatology, Microbiology, 03 medical and health sciences, Drug Therapy, Pharmacology, Hepaciviru, Flaviviruses, lcsh:R, Organisms, Correction, medicine.disease, Prospective Studie, Regimen, Immunology, lcsh:Q, RNA viruses, lcsh:Medicine, 030204 cardiovascular system & hematology, medicine.disease_cause, Cohort Studies, Liver disease, Drug Metabolism, Medicine and Health Sciences, 030212 general & internal medicine, Prospective cohort study, Pathology and laboratory medicine, Multidisciplinary, HCV DAA, Hepatitis C virus, Antiviral therapy, Medical microbiology, Hepatitis C, Real life data, Research Design, Combination, Viruses, Pathogens, Research Article, Liver Cirrhosi, Biology, Research and Analysis Methods, Chronic hepatitis, Internal medicine, Pharmacokinetics, In patient, Antiviral Agent, Biology and life sciences, Toxicity, business.industry, Interferon free, Viral pathogens, Hepatitis viruses, Microbial pathogens, business
Abstract

Background There are few real-life data on the potential drug-drug interactions (DDIs) between anti-HCV direct-acting antivirals (DAAs) and the comedications used. Aim To assess the potential DDIs of DAAs in HCV-infected outpatients, according to the severity of liver disease and comedication used in a prospective multicentric study. Methods Data from patients in 15 clinical centers who had started a DAA regimen and were receiving comedications during March 2015 to March 2016 were prospectively evaluated. The DDIs for each regimen and comedication were assigned according to HepC Drug Interactions (www.hep-druginteractions.org). Results Of the 449 patients evaluated, 86 had mild liver disease and 363 had moderate-to-severe disease. The use of a single comedication was more frequent among patients with mild liver disease (p = 0.03), whereas utilization of more than three drugs among those with moderate-to-severe disease (p = 0.05). Of the 142 comedications used in 86 patients with mild disease, 27 (20%) may require dose adjustment/closer monitoring, none was contraindicated. Of the 322 comedications used in 363 patients with moderate-to-severe liver disease, 82 (25%) were classified with potential DDIs that required only monitoring and dose adjustments; 10 (3%) were contraindicated in severe liver disease. In patients with mild liver disease 30% (26/86) used at least one drug with a potential DDI whereas of the 363 patients with moderate-to-severe liver disease, 161 (44%) were at risk for one or more DDI. Conclusions Based on these results, we can estimate that 30–44% of patients undergoing DAA and taking comedications are at risk of a clinically significant DDI. This data indicates the need for increased awareness of potential DDI during DAA therapy, especially in patients with moderate-to-severe liver disease. For several drugs, the recommendation related to the DDI changes from “dose adjustment/closer monitoring”, in mild to moderate liver disease, to “the use is contraindicated” in severe liver disease.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results